3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Warts
2
Melanoma
2
Hyperthermia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Cisplatin
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
Paclitaxel
6
Platinum
5
Cyclophosphamide
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
4
durvalumab
4
cemiplimab
4
Radiotherapy, Intensity-Modulated
4
Radiotherapy
3
Pemetrexed
3
Oxaliplatin
3
Nivolumab
3
Fluorouracil
3
Cetuximab
3
Carboplatin
3
Biopsy
3
poly ICLC
2
fludarabine phosphate
2
cabozantinib
2
atezolizumab
2
Radiation
2
Ipilimumab
2
Interviews as Topic
2
Heavy Ion Radiotherapy
2
Gemcitabine
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled